Share on StockTwits

Karyopharm Therapeutics (NASDAQ:KPTI) major shareholder Marcin Czernik sold 8,027 shares of Karyopharm Therapeutics stock on the open market in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $39.11, for a total value of $313,935.97. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Karyopharm Therapeutics (NASDAQ:KPTI) traded down 1.62% on Monday, hitting $38.18. 88,647 shares of the company’s stock traded hands. Karyopharm Therapeutics has a 1-year low of $15.50 and a 1-year high of $47.98. The stock has a 50-day moving average of $37.24 and a 200-day moving average of $34.42. The company’s market cap is $1.247 billion.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings data on Thursday, August 7th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.52. Analysts expect that Karyopharm Therapeutics will post $-2.19 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Leerink Swann cut their price target on shares of Karyopharm Therapeutics from $63.00 to $60.00 in a research note on Friday, August 8th. Analysts at Oppenheimer downgraded shares of Karyopharm Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, July 7th. One equities research analyst has rated the stock with a hold rating and two have given a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $52.67.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.